Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509911 | 1.00 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8029752 | 0.88 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5154770 | 0.83 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31240957 | 0.83 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL667942 | 0.83 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9838572 | 0.81 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18855065 | 0.81 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17377389 | 0.79 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11788741 | 0.79 | ACHE (0.56) | ALDH1A1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL11789375 | 0.79 | GAA (0.41) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3853172-B1 | METHODS FOR PREPARING ARYLPHOSPHINE-BORANE COMPLEXES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-07-05 | — | — | EP | claimed |
| EP-3601303-B1 | METHODS FOR FORMING 1,3,5,7-TETRAALKYL-6-(2,4-DIMETHOXYPHENYL)-2,4,8-TRIOXA-6-PHOSPHAADAMANTANE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-04-13 | — | — | EP | claimed |
| US-20210380613-A1 | METHODS FOR PREPARING ARYLPHOSPHINE-BORANE COMPLEXES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-12-09 | — | — | US | claimed |
| US-11111260-B2 | Methods for forming 1,3,5,7-tetraalkyl-6-(2,4-dimethoxyphenyl)-2,4,8-trioxa-6-phosphaadamantane | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-09-07 | — | — | US | claimed |
| EP-3853172-A1 | METHODS FOR PREPARING ARYLPHOSPHINE-BORANE COMPLEXES | Dow Global Technologies LLC (US) | 2021-07-28 | — | — | EP | claimed |
| WO-2020061151-A1 | METHODS FOR PREPARING ARYLPHOSPHINE-BORANE COMPLEXES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-03-26 | — | — | WO | claimed |
| EP-3601303-A1 | METHODS FOR FORMING 1,3,5,7-TETRAALKYL-6-(2,4-DIMETHOXYPHENYL)-2,4,8-TRIOXA-6-PHOSPHAADAMANTANE | Dow Global Technologies LLC (US) | 2020-02-05 | — | — | EP | claimed |
| US-20200010494-A1 | METHODS FOR FORMING 1,3,5,7-TETRAALKYL-6-(2,4-DIMETHOXYPHENYL)-2,4,8-TRIOXA-6-PHOSPHAADAMANTANE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-01-09 | — | — | US | claimed |
| WO-2018175671-A1 | METHODS FOR FORMING 1,3,5,7-TETRAALKYL-6-(2,4-DIMETHOXYPHENYL)-2,4,8-TRIOXA-6-PHOSPHAADAMANTANE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-09-27 | — | — | WO | claimed |
| EP-1354886-B1 | Process for the preparation of tertiary phosphines | SALTIGO GMBH (DE) | 2009-08-26 | — | — | EP | claimed |
| US-7230136-B2 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | claimed |
| US-20030229240-A1 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | US | claimed |
| EP-1354886-A1 | Process for the preparation of tertiary phosphines | Bayer Aktiengesellschaft (DE) | 2003-10-22 | — | — | EP | claimed |
| US-11999674-B2 | Butadiene telomerization catalyst preparation and use thereof | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230331643-A1 | BUTADIENE TELOMERIZATION CATALYST PREPARATION AND USE THEREOF | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-11713286-B2 | Butadiene telomerization catalyst preparation and use thereof | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-20070299273-A1 | prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example | LANXESS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| US-7230136-B2 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20030229240-A1 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1354886-A1 | Process for the preparation of tertiary phosphines | Bayer Aktiengesellschaft (DE) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713286-B2 | Butadiene telomerization catalyst preparation and use thereof | TELO2, TERT, TPR | CA12 4546/4885CA1 4173/4885CA2 4531/4885 |
| US-20200010494-A1 | METHODS FOR FORMING 1,3,5,7-TETRAALKYL-6-(2,4-DIMETHOXYPHENYL)-2,4,8-TRIOXA-6-PHOSPHAADAMANTANE | LPAR6, DDX6, AS3MT | CA12 2368/4885CA1 441/4885CA2 629/4885 |
| US-20230331643-A1 | BUTADIENE TELOMERIZATION CATALYST PREPARATION AND USE THEREOF | TELO2, TERT, TPR | CA12 4546/4885CA1 4173/4885CA2 4531/4885 |
| US-11111260-B2 | Methods for forming 1,3,5,7-tetraalkyl-6-(2,4-dimethoxyphenyl)-2,4,8-trioxa-6-phosphaadamantane | LPAR6, DDX6, AS3MT | CA12 2368/4885CA1 441/4885CA2 629/4885 |
| US-11999674-B2 | Butadiene telomerization catalyst preparation and use thereof | TELO2, TERT, TPR | CA12 4546/4885CA1 4173/4885CA2 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.